Maze Therapeutics, Inc.
MAZENASDAQ
Healthcare
Biotechnology
$28.82
-0.23(-0.8%)
52W $7.57 – $51.84
Maze Therapeutics, Inc.
$1.4BMkt Cap
—Rev TTM
-$133MNI TTM
-17.8xP/E TTM
Latest Earnings
10-K
FY FY2025Mar 24, 2026Maze Therapeutics, Inc. (MAZE) reported a net loss of $131.1 million for FY 2025 ending December 31, 2025, compared to net income of $52.2 million in FY 2024, primarily due to the absence of $167.5 million in license revenue recognized in 2024 from agreements with Shionogi, Trace, and Neurocrine. Operating expenses rose to $142.9 million from $109.9 million YoY, driven...
What Changed Recently
Fundamentals
How The Business Makes Money
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Industry Biotechnology
Company Profile
CIK0001842295
ISINUS5787841007
CUSIP578784100
Phone650 850 5070
Address171 Oyster Point Blvd, South San Francisco, CA, 94080, US
SEC EDGAR